Drug Trial Radar · NCT00203476
A Prospective, Open Label Comparison of Ezetimibe, Niacin, and Colestipol as Adjunct Therapy in Lipid Reduction
Last checked: Nov 20, 2026Latest source record: Aug 12, 2014 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
30
Actual
Start
May 2005
Primary completion
Jan 2008
Study completion Jan 2008
Sponsor
- Lead sponsor
- Tuscaloosa Research & Education Advancement CorporationAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- American Society of Health-System Pharmacists Research and Education Foundation
- First posted
- Sep 20, 2005
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 50 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To compare LDL reduction compared to baseline in patients using maximum tolerated HMG CoA Reductase inhibitor (statin) therapy with adjunctive therapy with ezetimibe, colestipol, or niacin. The patient's cardiovascular risks are assessed to determine if National Cholesterol Education Program's Adult Treatment Panel III (NCEP ATP III) guidelines for low density lipoprotein (LDL) reduction were achieved between the three groups. Secondary measures examine the safety issues with liver function test (LFT) monitoring and rhabdomyolysis. High-density lipoproteins (HDL) elevations are monitored between the three groups to determine efficacy as a secondary outcome.
Conditions
- Hyperlipidemia
- Hypercholesterolemia
Interventions
NiacinDrug
ColestipolDrug
EzetimibeDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- LDL Goal AttainmentTime frame: 12 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Tuscaloosa Research & Education Advancement Corporation
Tuscaloosa, Alabama
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.